|
|
News Breaks | | | | March 10, 2013 | | 15:15 EDT |  | MDCO | The Medicines Co's.Cangrelor show favorable results in ischemic events
The Medicines Company reported results of CHAMPION PHOENIX, a 11,145 patient Phase 3 randomized, double-blind clinical trial comparing the Company's intravenous antiplatelet cangrelor to oral clopidogrel in patients undergoing percutaneous coronary intervention, PCI. Patients treated with cangrelor had a 22% (p=0.005) reduced odds of experiencing the primary endpoint, which was a composite incidence of death, myocardial infarction (MI), ischemia-driven revascularization, IDR, or stent thrombosis, ST, at 48 hours after randomization. Cangrelor also showed a 38% reduction in the odds of the key secondary endpoint, incidence of stent thrombosis at 48 hours. The findings were consistent across all analyzed subgroups of patients, including age, geography, diagnosis at presentation, and the choice of periprocedural anticoagulant. At 30 days, the rate of the composite primary efficacy end point remained significantly lower in the cangrelor group than in the clopidogrel group and the relative reduction in stent thrombosis also persisted. Commenting on the results, Simona Skerjanec PharmD, MBA, Senior Vice President and Innovation Leader for Antiplatelet Therapies at The Medicines Company, said: "With successful completion and reporting of this Phase 3 trial, our next step is to submit for market approvals in the US and Europe. We anticipate submitting these data for a new drug application to the US Food and Drug Administration in the second quarter with findings of prior trials, including the BRIDGE trial in patients awaiting open heart surgery." | |
|
News For MDCO From The Last 14 Days Check below for free stories on MDCO the last two weeks. |
|
|
| May 23, 2013 | | 07:48 EDT |  | MDCO | The Medicines Co. decline unjustified, says RBC Capital
 Subscribe for More Information | | | May 22, 2013 | | 15:16 EDT | | MDCO | The Medicines Co. shares defended at ISI Group
Subscribe for More Information | | | May 21, 2013 | | 12:13 EDT | | MDCO | The Medicines Co. weakness a buying opportunity, says Credit Suisse
Subscribe for More Information | | | 11:49 EDT | | MDCO | The Medicines Co. weakness not related to fundamentals, says ISI Group
ISI Group said they spoke with The Medicines Company management and haven't found anything fundamental to explain today's weakness. The analyst also confirmed there was nothing new regarding the ongoing Angiomax litigation with the Judge's office and said today's AcelRx Ph. 3 data provided no new information. | | | 10:24 EDT |  | MDCO | The Medicines Co. spike lower, levels to watch
Subscribe for More Information | | | 10:21 EDT |  | MDCO | The Medicines Co. increases on wide intra-day price movement
The Medicines Co. June call option implied volatility is at 42, July is at 53, October is at 49; compared to its 26-week average of 39 according to Track Data, suggesting large price movement. | | | 10:16 EDT | | MDCO | The Medicines Co. falls 17.5% to $29.37
| |
|
|
|
|
|
|
